News

Trequant Launches a Wearable, Watch-like Device to Monitor Tremors

Trequant, Inc., a wearable device startup, is launching a Kickstarter campaign to raise money to market and further develop its tremor quantifying device. The Trequant wearable is designed to appear and feel like a normal analog watch, but contains advanced sensors that monitor the extremity tremors common to movement disorders like Parkinson’s disease…

Suppressing Brain Immune Responses of Parkinson’s Patients Gives Promising Therapeutic Approach

Inhibitors of the JAK/STAT pathway may provide potential for treating patients with neurodegenerative diseases, particularly Parkinson’s, by reducing the degenerative inflammation in the brain according to the study “Inhibition of the JAK/STAT pathway protects against α-synuclein-induced neuroinflammation and dopaminergic neurodegeneration“, published May 4 in The…

Dopamine Therapy for Parkinson’s May Be Possible Using Neurons Transplants with On and Off Switches

Therapies intending to increase dopamine levels in the brains of Parkinson’s patients have struggled to adequately regulate signaling. But researchers have now engineered transplant dopamine neurons that might be switched on or off using designer drugs — suggesting these transplants might be a viable way of treating Parkinson’s via dopamine release after…

Neuronal Changes Seen in Parkinson’s Mouse Model Well Before Disease Symptoms

University of Texas Health Science Center researchers have identified physiologic changes in dopamine neurons in a key animal model of Parkinson’s known to display disease symptoms, the MitoPark mouse model. The dopamine changes in the mice, however, clearly came before any symptoms appeared — findings that may lead to earlier identification of  Parkinson’s in people,…

Phase 2b Results of Parkinson’s Disease Drug Presented by Acorda

Acorda Therapeutics recently presented results from a Phase 2b study of its investigational drug CVT-301 in patients with Parkinson’s disease (PD) at the 68th Annual Meeting of the American Academy of Neurology in Vancouver, Canada. “Approximately 350,000 people with PD in the U.S. experience OFF periods, which can be very disruptive. There…